Bristol-Myers Squibb Bristol-Myers Squibb Company (NYSE: BMY) was founded in 1887 and is headquartered in New York City, New York, USA. It has 23,700 employees worldwide. It is a scientific research-based multinational biopharmaceutical, healthcare and personal care product leader , Its main business consists of 3 pieces: biopharmaceuticals, medical equipment, consumer goods & beauty products & nutrition.
Bristol-Myers Squibb (BMY):
Bristol-Myers Squibb (BMS) is a multinational pharmaceutical company that originated in the United States. It was formed in 1989 by the merger of two major US pharmaceutical companies, Bristol-Myers and Squibb. The former was founded in 1887 by William McLaren Bristol and John Ripley Mills in Clinton Village, Oneida County, New York, and the two founders were both local Hamilton Graduates of the College (New York); the latter was founded in Brooklyn in 1858 by inventor Edward Robinson Squibb.
Bristol-Myers Squibb is committed to the research and development of new drugs. The medical field includes cancer treatment, cardiovascular, infectious diseases and metabolic syndrome, and has a certain leading position. Its wholly-owned subsidiaryMead (Mead Johnson, 2017 Nian 2 10 February, Reckitt Benckiser for $ 90 per share in cash, a $ 16.6 billion, even total liabilities of $ 17.9 billion acquisition of baby food maker Mead (Mead Johnson))ConvaTec (ConvaTec, a company specializing in the production of medical-related business products, including ostomy, wound treatment products, skin and wound care products), is dedicated to the research and development of nutrition and health/rehabilitation products.
Bristol-Myers Squibb is a global leader in the development of innovative drugs for the treatment of cardiovascular diseases, metabolic and infectious diseases, central nervous system diseases, skin diseases, AIDS and cancer. Bristol-Myers Squibb is also a world leader in the development and production of consumer self-treatment drugs, infant formula milk powder and hairdressing products.
Bristol-Myers Squibb is a multinational industrial giant with more than 23,000 employees, operations in more than 60 countries and regions, and annual sales of more than 16 billion US dollars. After more than 120 years of development, Bristol-Myers Squibb has grown from a global Of pharmaceutical and health products company successfully transformed into a leader in biopharmaceuticals.
Bristol-Myers Squibb Company provides various therapeutic drugs, such as oncology, cardiovascular disease, immunoscience, and virology, including human immunodeficiency virus (HIV) infection, etc. (for specific products, please refer to the introduction below).
Bristol-Myers Squibb (BMY) product:
Involved areas :
- Milk powder: The well-known Mead Johnson brand is a brand of Bristol-Myers Squibb( Acquired by Li Jieshi in February 2017 )
- Wound care: Kangfubao brand, the main products include stoma, wound treatment products, skin and wound care products.
- Medical equipment: bone correction & bone formation products, etc.
- Drugs: Cardiovascular drugs, anticancer drugs, and central nervous system drugs are the most famous. Such as Jinshierkang, Shierkang, and Weikangfu in the Jinshierkang series; Isovue brand anti-delusion drugs, and Lipostat ester antihypertensive.
- Over-the-counter health care products: Gerber brand infant health care equipment and other nutritional vitamin products, pain relievers, skin medicines, etc.
- Cosmetics, fitness products and household products: including the well-known Miss clairol, Utless and Condition brand hair products, Sea Braze brand skin products, Vanish brand dishwashing detergent, etc.
Bristol-Myers Squibb (BMY) main pharmaceutical products:
1. Cardiovascular diseases
- Avalide (irbesartan/hydrochlorothiazide) — joint sales with Sanofi
- Avapro (irbesartan) — joint sales with Sanofi
- Coumadin (warfarin)
- Eliquis (apixaban) — joint sales with Pfizer
- Plavix (clopidogrel) -joint sales with Sanofi
- Pravachol (pravastatin)
2. Diabetes (Diabetes mellitus)
- Bydureon (exenatide extended-release)
- Byetta (exenatide)
- Glucophage (metformin) — BMS is only available in USA
- Glucophage XR (metformin extended release) — BMS is only sold in USA
- Glucovance (glyburide/metformin) — BMS is only available in USA
- Kombiglyze XR/Komboglyze (saxagliptin/metformin extended release) — joint marketing with AstraZeneca
- Onglyza (saxagliptin)-joint marketing with AstraZeneca
3. Infectious diseases, including HIV infection and associated conditions (Infectious diseases, including HIV infection and associated conditions)
- Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate) — joint marketing with Gilead Sciences
- Azactam (aztreonam)
- Baraclude (entecavir)
- Daklinza (daclatasvir)
- Evotaz (atazanavir/cobicistat)
- Megace (megestrol acetate)
- Reyataz (atazanavir)
- Sustiva/Stocrin (efavirenz)
- Videx (didanosine)
- Videx EC (didanosine sustained release)
- Zerit (stavudine)
4. Inflammatory disorders
- Kenalog-10 (triamcinolone acetonide)
- Kenalog-40 (triamcinolone acetonide)
- BiCNU (carmustine)
- CeeNU (lomustine)
- Droxia/Hydrea (hydroxycarbamide)
- Empliciti (Elotuzumab)
- Erbitux (cetuximab)
- Etopophos (etoposide)
- Ixempra (ixabepilone)
- Lysodren (mitotane)
- Megace (megestrol acetate)
- Opdivo (nivolumab)
- Sprycel (dasatinib)
- Taxol (paclitaxel)
- Vumon (teniposide)
- Yervoy (ipilimumab)
- Abilify (aripiprazole) -joint marketing with Japan Otsuka Pharmaceutical (Otsuka Pharmaceutical Co., Ltd., TYO: 4578)
7. Rheumatic disorders
- Orencia (abatacept)
8. Transplant rejection
- Nulojix (belatacept)
Bristol-Myers Squibb (BMY) History Encyclopedia:
1. Bristol-Myers History:
- In 1887, the Clinton Pharmaceutical Company, founded by William McLaren Bristol and John Ripley Myers in Clinton, New York, was the predecessor of Bristol-Myers Squibb
- In 1898 changed its name to Bristol, Myers Company (Bristol, Myers Company)
- In 1900, the company was registered as a share branch, and its business focus shifted to the wholesale and retail of pharmaceuticals
- In 1924, the company’s products were sold to 26 countries
- In 1929, the company’s stock was listed in New York
- In 1943, the company acquired Cheplin Laboratories (Cheplin Laboratories), and mass production of penicillin and antibiotics for Allied forces.
- Acquired Clairol, a wig manufacturer, in 1959.
- Acquired Drakett, a manufacturer of household products, in 1965
- In 1972, acquired surgical products company Zimmer Manufacturing Company
- In 1978, Unitek, a manufacturer of dental products, was acquired
- From 1974 to 1980, the company launched 11 new anti-cancer drugs on the market, bringing the company a profit of 200 million US dollars
- In 1986, the company merged with the biotech company Gene Systems Corporation (GSC). During this period, the company also achieved a prominent market position in the treatment and control of AIDS.
2. Squibb History:
- In 1856, Dr. Edward R. Squibb (Edward Robinson Squibb) founded the Squibb Company in Brooklyn, New York, to produce pure ether.
- In 1905, Bristol-Myers Squibb’s son sold the company to Theodore Wick , founder of Merck .
- Between 1909 and 1929, the company’s annual sales soared from US$414,000 to US$130 million.
- During World War II, the company became a major supplier of morphine and penicillin.
- In 1946, the company expanded to Latin America, Europe and other places, setting up manufacturing plants in Mexico, Italy and Argentina.
- In 1971, the company changed its name to Squibb Co., Ltd.
- In 1975, annual sales reached 1 billion US dollars.
3. Bristol-Myers Squibb History:
- In 1989, Bristol-Myers and Squibb merged to form the current Bristol-Myers Squibb
- In 1990, the Bristol-Myers Squibb Pharmaceutical Research Institute was established in Princeton (Princeton)
- In 1991, the National Tumor Research Association authorized Bristol-Myers Squibb to develop new anti-cancer drugs
- On December 29, 1992, the BMY research result—TAXOL®, was approved by the US Food and Drug Administration (FDA)
- In 1993, Bristol-Myers Squibb TAXOL was patented and put into production
- In 2007, Bristol-Myers Squibb acquired Adnexus Therapeutics
- In 2007, Bristol-Myers Squibb Medical Imaging, a subsidiary of Bristol-Myers Squibb, was sold to Avista Capital Partners
- In 2008, BMS sold its ConvaTec to Avista Capital Partners & Nordic Capital Fund VII
- In 2008, Bristol-Myers Squibb acquired Kosan Biosciences
- In 2009, Bristol-Myers Squibb acquired Medarex
- In 2009, Bristol-Myers Squibb divested Mead Johnson . On February 11, 2009, Mead Johnson was listed on the New York Stock Exchange under the stock code MJN. Mead Johnson IPO issued 30 million shares, the issued share capital accounted for 15%, the issue price per share was 24 US dollars, the IPO raised funds of 720 million US dollars after the listing, the total number of shares of Mead Johnson increased to 200 million shares, accounting at the issue price of 24 US dollars per share , The company’s market value is 4.8 billion US dollars. After listing, Bristol-Myers Squibb will hold 83% of the shares.
- In 2010, Bristol-Myers Squibb acquired ZymoGenetics
- In 2011, Bristol-Myers Squibb acquired Amira Pharmaceuticals
- In 2012, BMS acquired Inhibitex Inc
- In 2012, Bristol-Myers Squibb acquired Amylin Pharmaceuticals, a joint venture with AstraZeneca
- In 2014, Bristol-Myers Squibb acquired iPierian
- In 2015, Bristol-Myers Squibb acquired Flexus Biosciences
- In 2015, Bristol-Myers Squibb acquired Cardioxyl
- In 2016, Bristol-Myers Squibb acquired Padlock Therapeutics
- In 2016, Bristol-Myers Squibb acquired Cormorant Pharmaceuticals
- In 2017, Bristol-Myers Squibb acquired IFM Therapeutics
- On January 3, 2019, Bristol-Myers Squibb announced that it would acquire New Fundamental Medicine (Xaar Gene) for a total of US$74 billion in cash and stock . The original shareholders of Xaar Gene can get 1 share of Bristol-Myers Squibb stock plus US$50 in cash for every 1 share and the expected value right (CVR) of US$9 in cash in the future. With the acquisition of Xaar Gene, BMS can obtain multiple product line assets with blockbuster potential in the fields of tumor, immunity, and inflammation, including TYK2, ozanimod, luspatercept, liso-cel (JCAR017), bb2121, fedratinib, etc.